Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject in need thereof.

Abstract: Methods and materials for development of high-throughput screening assays using aptamers are provided by this invention.

Abstract: Methods and materials for development of high-throughput screening assays for detection of cyclic GMP (cGAMP) are provided by this invention.

Abstract: Methods and materials for development of high-throughput screening assays for detection of cyclic GMP (cGAMP) and/or cyclic GMP-AMP synthase (cGAS) activity are provided by this invention.

Abstract: Methods and materials for development of high-throughput screening assays using split aptamers are provided by this invention.

Abstract: The present invention relates to novel engineered Ga proteins and assay methods of using such proteins to advance drug discovery. Engineered Ga proteins described by the invention contain alterations of at least one and preferably two or more amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A preferred engineered protein disclosed here is a double mutant, G?? R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function both in terms of GTPase activity (GTP hydrolysis) and GDP dissociation. This synergistic effect may have a profound influence on the way GPCR signaling pathways are examined for the development of new pharmacotherapies, particularly in the field of central nervous system disorders such as Parkinson's disease.

Abstract: This invention provides methods to determine the activity of methyltransferase enzymes which employ S-adenosylmethionine (SAM) as a substrate and transfer a methyl group to convert this substrate to S-adenosylhomocysteine (SAH), by measuring SAH conversion to AMP.

Abstract: A non-competitive immunoassay method for detection of post-translationally modified (PTM) proteins is disclosed. The method will enable the direct detection of PTM proteins in solution or on solid phase with a single reagent addition step, and with improved selectivity for specific PTM sites on target proteins. The key to the method is the use of a secondary binding molecule that specifically recognizes the immune complex between the primary antibody and the antigen. The use of a secondary binding molecule will increase the sensitivity and selectivity of antigen detection compared to use of the primary antibody alone. The use of a secondary binding molecule also allows direct, homogenous detection rather than competition with a labeled tracer, because the secondary binding molecule can be labeled with a detection reagent that interacts with a detection reagent on the primary antibody.

Abstract: The present invention relates to novel engineered Ga proteins and assay methods of using such proteins to advance drug discovery. Engineered Ga proteins described by the invention contain alterations of at least one and preferably two or more amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A preferred engineered protein disclosed here is a double mutant, G?? R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function both in terms of GTPase activity (GTP hydrolysis) and GDP dissociation. This synergistic effect may have a profound influence on the way GPCR signaling pathways are examined for the development of new pharmacotherapies, particularly in the field of central nervous system disorders such as Parkinson's disease.

Abstract: The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention.

Abstract: The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention.

Abstract: The present invention provides a novel microscale fluid handling system for initiating, culturing, manipulating and assaying three-dimensional multicellular assembly. The system including a microfluidic device and three-dimensional multicellular tissue surrogate assembly. The device of the invention includes at least one microfluidic channel; and at least one chamber, wherein the walls of the chamber are lined with a cell layer; and wherein fluid medium flows through each of the channels and chambers. Also, disclosed are methods for using the device to introducing test agents to the multicellular assemblies to observe biological responses thereof.

Abstract: The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention.

Abstract: A fluorescence polarization process used to identify activity of conjugative enzymes involved in xenobiotic transformations, such as glucuronosyltransferases is provided.

Abstract: A fluorescence polarization process used to identify activity of conjugative enzymes involved in xenobiotic transformations, such as glucuronosyltransferases is provided.

Abstract: A fluorescence polarization process used to identify activity of conjugative enzymes involved in xenobiotic transformations, such as glucuronosyltransferases is provided.

Abstract: The system comprises mixing a fluorescence-emitting compound that binds to the steroid hormone receptors in a solution containing the steroid hormone receptors. Then, measuring the fluorescence polarization of the solution. Subsequently, incubating the solution with at least one molecule that may compete with the compound for interaction with the steroid hormone receptors. Measuring the fluorescence polarization of the solution again. Finally, comparing the fluorescence polarization measurements to quantify any competitive interaction.

Abstract: A method is provided for measuring competitive binding activity of molecules to nuclear receptors comprising mixing a fluorescence-emitting compound that specifically binds to steroid hormone receptors in a solution wherein the fluorescence-emitting compound is in concentration below the dissociation constant and the steroid hormone receptors are at or above the dissociation constant using fluorescence polarization.